Corient Private Wealth
AVBP icon

Corient Private Wealth’s ArriVent BioPharma AVBP Stock Holding History

Corient Private Wealth’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$710K Sell
20,430
-6,809
-25% -$201K ﹤0.01% 1997
2026
Q1 		$608K Buy
+27,239
New +$615K ﹤0.01% 1929
2025
Q4 		– Sell
-33,500
Closed -$618K – 2824
2025
Q3 		$618K Buy
+33,500
New +$658K ﹤0.01% 1680

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Corient Private Wealth's AVBP Position: Q2 2026 in Review

Corient Private Wealth reduced its ArriVent BioPharma (AVBP) stake by 25% in Q2 2026, selling an estimated $201K and leaving 20,430 shares worth $710K. The position accounts for ﹤0.01% of the portfolio, ranked #1997.

Corient Private Wealth first reported a position in AVBP in Q3 2025 and has held it in 3 quarters since. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Corient Private Wealth held 20,430 shares of ArriVent BioPharma worth $710K as of Q2 2026.
  • Corient Private Wealth sold 6,809 ArriVent BioPharma shares in Q2 2026, an estimated $201K.
  • ArriVent BioPharma made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #1997 holding.
  • Corient Private Wealth first reported a position in ArriVent BioPharma in Q3 2025 and has held it in 3 quarters since.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.